Reovirus has an inherent preference for replicating in cells with dysregulated growth factor signaling cascades that comprise Ras activation. Precisely how reovirus exploits the host cell Ras pathway is unclear, but there is evidence suggesting that activated Ras signaling is important for efficient viral protein synthesis. Defining the molecular mechanism of reovirus oncolysis will shed light on reovirus replication and important aspects of cellular transformation, Ras signaling cascades and regulation of protein translation. Oncogene (2005) 24, 7720-7728.
Many exciting developments have been made in the last two decades with respect to the use of replicationcompetent viruses as specific oncolytic agents. A handful of oncolytic viruses have been identified. Some naturally occurring viruses preferentially infect and kill transformed cells, such as vesicular stomatitis virus (VSV), herpes simplex virus (HSV), Newcastle disease virus (NDV) and reovirus (Norman and Lee, 2000; Stojdl et al., 2000; Sinkovics and Horvath, 2000; Farassati et al., 2001) . The Edmonston-B strain of measles virus (MV-Edm), originally attenuated for use as a live virus vaccine, has potential oncolytic application (Grote et al., 2001) . Furthermore, several genetic modifications to adenoviruses, influenza viruses and herpes viruses have been shown to confer selective oncolytic activity (Martuza, 2000; Bergmann et al., 2001; Dobbelstein, 2004) . A growing body of research demonstrates that these viruses can efficiently and selectively destroy transformed cell lines and also have antitumor properties in vivo. Exciting developments have also been made in understanding the molecular bases of viral oncolysis.
The use of replication-competent viruses for oncolysis depends on their ability to selectively infect and destroy cancer cells. Viruses have evolved intricate strategies to ensure efficient replication in the host cell. Viral encoded factors can alter the regulation of cellular processes important for viral replication. Processes amicable to viral replication are provoked, while those that are detrimental for replication are prevented. For example, DNA viruses that require cell division for viral genome replication have evolved strategies to ensure that cells proliferate. Cellular responses that would clear viral infections such as apoptosis, interferon (IFN)-induced antiviral activities and presentation of viral antigens by multihistocompatibility class I (MHC-I) molecules are overcome to different extents by various viruses. In view of such highly evolved strategies to ensure efficient replication in cells, how can viruses be used specifically to kill cancer cells?
With increased understanding of virus replication, viral-cell interactions and methods to manipulate viral genomes, viruses have been generated that are no longer able to regulate specific host processes. The deletion of viral proteins important in regulating cellular processes can, therefore, create viruses that are unable to replicate in normal cells. Conversely, cellular events involved in tumorigenesis, such as increased cell division and dysregulated cell death programs, make tumor cells permissive to replication by these recombinant viruses. ONYX-015 is an example of an engineered oncolytic virus, and is described thoroughly by Clodagh O'Shea and Frank McCormick in this edition of Oncogene reviews. The engineered ONYX-015 virus is unable to make E1B-55K, an early adenoviral protein critical for degrading p53 and thus overcoming p53-mediated cell cycle arrest and apoptosis (Biederer et al., 2002) . The selective oncolysis by ONYX-015 is likely in part due to the dysregulation of p53 pathways in susceptible tumor cells. Interestingly, it was recently discovered that following infection with ONYX-015 efficient export of late adenoviral RNA from the nucleus is restricted to tumor cells (O'Shea et al., 2004) . This finding shows that novel and unperceived differences between tumor and normal cells can affect virus replication.
Remarkably, reoviruses show an inherent preference for replication in many transformed cells. Possible explanations for why such a preference may have developed through the evolution of reovirus are discussed in this review. Reoviruses, the prototype member of the Reoviridae family, were first isolated from the intestinal tracts of apparently healthy individuals. In fact, most people have been exposed to reovirus by the age of 5 with little or no manifestation of symptoms. Hence, there are fewer concerns about the safety of using reovirus in cancer treatment. As this review will describe in detail, an understanding of the cellular events that contribute to the conditional replication of reovirus is emerging. Growth factor receptor signaling is intimately related with tumor progression. Genetic changes resulting in constitutive activation of growth factor signaling pathways result in uncontrolled proliferation, differentiation and/or metastasis, and are associated with most if not all human cancers. Intriguingly, reovirus replication is sensitive to the status of signaling cascades downstream of specific tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR). The pathways downstream of tyrosine kinase receptors are not only numerous, but are complicated by extensive cross-talk. Untangling the large networks of interactions coupled with cell signaling and phenotypic alterations associated with cancer is a challenge. Therefore, not only is reovirus a promising oncolytic agent but also reovirus replication offers a unique approach to understanding the components and outcomes of signal transduction pathways aberrantly regulated in cancer.
Intracellular signaling pathways involved in selective replication of reovirus
How the link between selective reovirus replication and cancer was discovered Differences between virally or spontaneously transformed cell lines and primary or untransformed cells with respect to their susceptibility to reovirus cytotoxicity were first noted in 1977 (Hashiro et al., 1977) . Likewise, human lung fibroblast cells (WI-38) showed enhanced permissibility to reovirus replication when they were transformed with the simian virus 40 Tantigen (Duncan et al., 1978) . Nevertheless, it was not until the 1990s that clues were obtained regarding the molecular basis of the selective replication of reovirus in transformed cells.
Receptor specificity often dictates the tropism of viruses (Cohen et al., 1988; Schneider-Schaulies, 2000; Sieczkarski and Whittaker, 2005) . When research on the determinants of selective oncolysis by reovirus began, it was known that the fibrous tail of the reovirus cell attachment protein, s1, bound sialic acid (Armstrong et al., 1984; Pacitti and Gentsch, 1987; Dermody et al., 1990; Chappell et al., 1997 Chappell et al., , 2000 . The ubiquitous nature of sialic acid, however, suggested that it could not account for gross differences in cell susceptibility. Since aberrations affecting tyrosine kinase receptors are often associated with transformation, the use of these receptors for reovirus entry propounded a potential link between transformation and permissiveness to reovirus infection. EGFR-minus mouse cell lines (NR6 and B82) were found to be relatively resistant to reovirus replication, while transfection of EGFR into these cells proved significantly advantageous for reovirus infection (Strong et al., 1993) . Interestingly, the involvement of EGFR in reovirus replication was found to be dependent on signaling pathways initiated through the tyrosine kinase receptor rather than receptor binding specificity. A mutated EGFR devoid of signaling capabilities was unable to confer permissiveness to reovirus replication, while the v-erbB oncoprotein, which lacks the extracellular ligand-binding domain but has a constitutively active kinase domain, was sufficient to permit reovirus infection (Strong et al., 1993; Strong and Lee, 1996) . Therefore, what started as a search for a secondary receptor for reovirus entry that could permit selective replication in transformed cells turned into a very interesting connection between the status of intracellular signaling pathways and the reovirus life cycle (Figure 1 ).
Involvement of Ras/RalGEF/p38 signaling pathways in reovirus replication
The interaction of growth factors with their cognate receptors results in the activation of a cascade of intracellular biochemical events leading to a cohort of cellular functions. Which cellular functions can affect reovirus replication? Which components of the signaling pathway are important? The EGFR signaling cascade initiates with receptor oligomerization and subsequent activation of tyrosine kinase activity resulting in autophosphorylation of specific tyrosine residues (Ullrich and Schlessinger, 1990; Fantl et al., 1993; Weiss and Schlessinger, 1998) . Adaptor molecules with phosphotyrosine binding, src homology 2 (SH2) domains are recruited to activated EGFR and in turn assemble a cohort of proteins particular to one of many downstream cascades (Pawson, 1994; Pawson and Scott, 1997; Buday, 1999) . The Ras signaling cascade is a major pathway downstream of EGFR (Campbell et al., 1998) . Ras proteins form a subfamily of small GTP-binding proteins involved in regulation of a wide variety of cellular function such as cell growth, differentiation and cell survival. Membrane-anchored Ras proteins cycle between the inactive GDP-bound state and the active GTPbound state. The activation of Ras proteins is promoted by guanine nucleotide exchange factors such as the Son of Sevenless (Sos), which are recruited by the previously described adaptor molecules to activated EGFRs (Overbeck et al., 1995) . With such an important role in cellular responses to activated EGFR, the Ras pathway became a logical target for possible involvement in conferring reovirus permissiveness.
Thorough analysis showed that an activated Ras signaling pathway plays an integral role in reovirus infectivity. Cell lines expressing constitutively active oncogenes of Sos or Ras were found to be permissive to reovirus infection . Importantly, when activated Ras was placed under a zinc-inducible promoter, a productive infection by reovirus was only found in the presence of ZnSO 4 . This suggested that the activated Ras protein itself, but not secondary consequences of prolonged transformation, was sufficient to permit reovirus infection.
Of over 18 downstream effectors of Ras, the best characterized are the Raf kinase, the phosphatidylinositol 3-kinase (PI3-kinase) and the guanine exchange factors (GEFs) for the small G protein Ral pathways. Descriptions of these pathways are beyond the scope of this review, but have been provided by numerous other publications (Reuther and Der, 2000; Campbell and Der, 2004; Repasky et al., 2004) . Other laboratories studying the implications of Ras activation have created many useful tools for distinguishing between downstream pathways (White et al., 1995 Khosravi-Far et al., 1996; Rodriguez-Viciana et al., 1997) . Constitutively active Ras mutants (RasV12) with additional mutations deleterious for binding to specific effector molecules PI3K, RalGEF or Raf showed that reovirus infection was independent of signaling through Raf or PI3-kinase cascades (Norman et al., 2004) . Furthermore, an active mutant of RalGEF permitted efficient reovirus replication in the absence of activated Ras. A dominant-negative mutant of Ral, the target protein for RalGEF-mediated GDP/GTP exchange, rendered Rastransformed cells nonpermissive to reovirus. Therefore, there is significant data implicating the Ras/RalGEF pathway in selective reovirus replication.
The signaling pathways downstream of Ras are immensely complicated by the high degree of cross-talk and dependency on factors such as cell origin and extracellular environment. Since reovirus replication is dependent on one or more arms of the Ras signaling cascade, it provides a useful readout for determining downstream components of Ras. Interestingly, previous observations that reovirus replication is enhanced in cells subjected to stressful conditions such as UV prompted analysis on the role of stress-activated protein kinases. Studies showed that p38, but not c-Jun-Nterminal kinase (JNK), participates in establishing reovirus infectivity. An inhibitor of p38 activation (SB203580) suppressed reovirus replication in cells transfected with activated Ras and RalGEF (Norman et al., 2004) . The potential role of p38 in transformation has become important in the last few years (MartinBlanco, 2000) . The data obtained with the p38 inhibitor suggests that p38 is a downstream effector of RalGEF, a relationship previously proposed (Ouwens et al., 2002) . Alternatively, RalGEF and p38 may act as components of separate pathways that must converge for a commonly effect. Missing links between RalGEF activation, p38 activity and reovirus replication remain to be found. What effectors act to mediate the RalGEFp38 connection? What cascades lie downstream of RalGEF and p38?
Reovirus replication as a method of understanding the role of Ras signaling cascades in cancer Aberrations in Ras proteins have been implicated in cell proliferation, transformation, invasion and metastasis (Malumbres and Barbacid, 2001 Barbacid, , 2003 . Mutations in Ras proteins are associated with approximately 30% of all human cancers (Bos, 1989) . This number underestimates the true prevalence of activated Ras pathways in cancer, as mutations in upstream activators and (Janes et al., 1994; Tzahar and Yarden, 1998) . Of the many downstream effectors, Raf, PI3K and RalGEF have been clearly demonstrated to mediate the oncogenic properties of Ras (Marshall, 1996; Wolthuis and Bos, 1999; Feig and Buchsbaum, 2002; Feig, 2003; Campbell and Der, 2004) . Studies using effector domain mutants specific to one of Raf, PI3K and RalGEF pathways suggest that although each pathway can induce individual biological responses, all three pathways cooperate for complete cellular transformation. Although Ral, the target of RalGEF activity, has been associated with vesicle sorting, gene expression and cellular proliferation, other downstream effectors of RalGEF involved in cancer remain to be found. With reovirus replication as the readout, we hope to delineate essential components in Ras signaling and transformation and thereby provide a novel means of understanding the implication of signaling cascades in cancer. Understanding the connection between Ras signaling cascades and reovirus replication will also permit most effective use of reovirus as a cancer therapeutic, as it will suggest which cancers are susceptible to reovirus oncolysis.
Which step(s) of the reovirus life cycle is blocked in nonpermissive cells, and how?

Reovirus translation is blocked in untransformed cells
The selective replication of reovirus in Ras-transformed cells is evident by assessing the degree of reovirus protein expression and the formation of newly formed reovirus particles. What remains to be determined is the precise mechanism by which the Ras pathway impacts the reovirus life cycle. Figure 2 provides a simplified diagram of reovirus structure and life cycle from numerous studies (Tyler, 2001) . Reovirus contains 10 double-stranded RNA segments encapsulated by two concentric protein coats. In cell culture, upon receptor binding and endocytosis, reovirus undergoes sequential uncoating and is released from endosomes as a core particle (a single protein shell surrounding the dsRNA). Positive sense RNA is made within the reovirus core, released into the cytoplasm, and subsequently used for protein production using the cellular translation machinery. The primary stage of reovirus replication produces sufficient proteins and RNA to form subviral particles (cores) within localized cytoplasmic subdomains called viral factories. A second round of mRNA and protein production causes a gross amplification of viral particles that completely assemble and exit the cell upon lysis. Which step(s) within the reovirus replication cycle is affected by the state of Ras signaling?
Reovirus undergoes equivalent binding, entry and primary transcription in both Ras transformed and untransformed cells Norman et al., 2004) . Conversely, protein expression monitored through 35 S-methionine labeling and immunofluorescent microscopy detection with reovirus specific antibodies suggest that the expression of reovirus proteins is largely inefficient in untransformed cells. The increased expression of reovirus proteins in Ras-transformed cells correlates with increased virus titer. Present analysis therefore suggests that the block in reovirus replication resides between primary transcription and protein expression. From both a virology and a cancer perspective, it would be exciting to understand the 
Effects of PKR activation on reovirus translation
A principal mechanism for prohibiting translation initiation in response to viral infections and environmental stress involves phosphorylation of the alpha subunit of eukaryotic initiation factor-2 (eIF2) by double-stranded-RNA-dependent protein kinase (PKR) (Wek, 1994; de Haro et al., 1996; Brostrom and Brostrom, 1998) . Although PKR is always present at low levels, its expression is upregulated in response to IFN released by virally infected cells. Binding to doublestranded RNA results in PKR dimerization, autophosphorylation and activation. Phosphorylation of eIF2 by activated PKR precludes the formation of GTPbound eIF2 and thus prevents loading of Met-tRNA and formation of the 43S initiation complex (as is further described by Ian Mohr in this issue).
The possible involvement of PKR in reovirus replication was indicated by two observations: the reovirus S1 segment mRNA was previously shown to be a potent activator of PKR (Bischoff and Samuel, 1989) , and translation of reoviral mRNA was impaired in untransformed cells relative to cells transformed with activated Ras. Using a standard in vitro kinase assay to detect activation of PKR, Strong et al. (1998) found that PKR was phosphorylated in untransformed NIH3T3 cells in response to reoviral replication. Lack of PKR phosphorylation in reovirus infected Ras-transformed cells suggested that reovirus translation is spared in transformed cells because PKR is not activated. These studies did not determine whether PKR activation is a cause of, or a consequence of, cellular changes beneficial for reovirus infection. A relatively specific chemical inhibitor of PKR phosphorylation restored reovirus translation in untransformed cells, providing evidence for a direct role of PKR in determining resistance to reovirus replication. Most convincingly, reovirus protein expression was deficient in normal (PKR þ / þ ) mouse embryo fibroblasts (MEFs) but efficient in PKR À/À MEFs. A link between PKR inactivation and Ras signaling has already been suggested, and may be compounded by these findings on selective reovirus replication (Mundschau and Faller, 1994) . At present, observations suggest that PKR activation plays a role in determining resistance to reovirus infection.
Many questions remain to be resolved with respect to the relationship between PKR activation and reovirus replication. What is the mechanism of increased PKR activity in normal cells: increased PKR expression, increased PKR phosphorylation, and/or decreased activity of phosphatases that act on PKR and PKR substrates? What role, if any, do IFNs and dsRNA activation play in determining the outcome of reovirus infection in transformed and untransformed cells? What is the molecular connection between Ras/RalGEF/p38 signaling pathways and PKR activation? Is PKR the sole determinant of efficient reovirus replication? What other effectors could play a role in altering the efficiency of reovirus mRNA translation?
Undetermined role of IFN in establishing resistance to reovirus
As previously mentioned, PKR is a critical translation regulator of the type I IFN-induced antiviral response (Samuel, 2001) . Are the effects of PKR activity on reovirus translation inhibition attributed to the basal PKR population or PKR induced through secondary signaling cascades such as IFN? Preliminary data using IFN-specific antibodies suggest that reovirus protein expression is blocked in untransformed cells despite inhibition of autocrine IFN responses. Conversely, since reovirus protein expression in Ras transformed cells does not commence until 6-12 h postinfection, there is time for additional signaling molecules such as IFN to impact the resolution of virus infection.
Conditional oncolysis by NS1-mutated influenza virus, NDV and VSV has been found to be modulated by the state of IFN signaling (Pecora et al., 2002; Balachandran and Barber, 2004; Muster et al., 2004) . Interestingly, additional changes in translation regulation were shown to cooperate with an ablated IFN pathway for highest efficiency of VSV replication in transformed cells. It is possible that alternative pathways converge on similar effects, such as translational control, which in turn determine the outcome of viral infection.
Connections between PKR and cancer
While PKR was first associated with the IFN-mediated antiviral response, research has since suggested that it serves additional purposes within the cell. The connection between PKR, translational control and cancer has been reviewed thoroughly (Clemens, 2004) . Since translational control permits a rapid response to environmental conditions, it offers a critical step in regulating cellular processes. Translation initiation is thought to be the rate-limiting step of protein expression. The activities of proteins that regulate translation initiation, including PKR, affect the status of protein expression, and are therefore often altered during transformation. PKR is involved in cell growth control and differentiation (Chong et al., 1992; Koromilas et al., 1992; Donze et al., 1995) . Dominant-negative PKR mutants were found to induce tumorigenic transformation of mouse fibroblasts (Meurs et al., 1993; Barber et al., 1995) . When overexpressed, PKR was found to induce apoptosis and has been suggested to act as a tumor suppressor (Jagus et al., 1999; Donze et al., 1999) . PKR is also involved in signaling pathways that stimulate transcription of more than a hundred specific genes (Kumar et al., 1997; Cuddihy et al., 1999) . Although significant findings link PKR dysfunction with cancer, the presence of elevated levels of PKR kinase activity in some human cancers has stirred debate regarding the role of PKR in transformation (Nussbaum et al., 2003) . Through our studies on reovirus oncolysis, we hope to further understand the connection between PKR and Ras signaling pathways and the role of PKR in transformation.
Additional cellular contributors to the block in reovirus translation?
While current research supports the role for PKR in establishing conditional reovirus replication, we are also investigating the involvement of other protein expression determinants that coincide with cellular transformation and Ras signaling. Growth and proliferation often correspond with multiple effects that result in increased translation initiation of proteins. In addition to the decrease in phosphorylation of eIF2-alpha and PKR, translation is upregulated through increased activity of eIF2B (exchanges GTP for GDP on eIF2-alpha), increased phosphorylation of eIF4E (binds the 5 0 methylated guanosine cap structure of mRNA and recruits remaining initiation factors) and increased availability of eIF4E through phosphorylation of the 4E-binding protein (binds and inhibits the activity of eIF4E) (Clemens and Bommer, 1999) . Interestingly, the stress-activated p38 cell signaling cascade is associated with increased eIF4E phosphorylation and activation (Waskiewicz et al., 1997) . The effects of increased translation initiation during growth and transformation are not seen universally, but rather impact a select group of mRNA. Several characteristics make specific growth-dependent mRNA weakly translated in untransformed cells and sensitive to the changes in translation initiation associated with transformation (Willis, 1999; Pickering and Willis, 2005) . At a glance, it does not appear that reovirus transcripts share the characteristics known to give conditional translation initiation. However, it is possible that features of reoviral mRNA such as the absence of 3 0 polyadenylation (and hence lack of poly(A) binding protein-mediated mRNA circularization) and very short 5 0 UTRs make them poor targets for translation initiation in the absence of Ras transformation. What alternative cellular activities could contribute to differential translation of reovirus proteins in Ras-transformed and untransformed cells?
Another interesting observation is that the translation of cellular proteins is spared in untransformed cells despite the inhibition of reoviral protein translation. The differential treatment of viral and cellular mRNA could be explained by compartmentalization of reovirus mRNA and activated PKR. If reovirus proteins are translated within or around viral factories, for example, localized PKR inactivation could account for the block in translation of only reovirus transcripts. Alternatively, since reoviral mRNAs are not polyadenylated, have very short 5 0 and 3 0 untranslated regions (UTRs) and are made in the cytoplasm in the absence of nuclear RNA binding proteins, they may be distinguished from cellular transcripts. Again, mRNA degradation cannot explain these phenomena since transcripts appear in equivalent amounts in both transformed and untransformed cells. Instead, this possibility requires a mechanism for specific translational silencing of reovirus transcripts. Poorly understood specific regulatory systems have been proposed to function in separating cellular translatable (polysomal) and untranslatable free mRNA/protein complexes (Minich and Ovchinnikov, 1992; Spirin, 1994; Matsumoto et al., 1998; Mazumder et al., 2001; Skabkin et al., 2004) . Translational masking as a specific antiviral response against cytoplasmic viral transcripts, however, has not yet been discovered. Whether translation of reovirus RNAs are actively and specifically silenced or inherently weak relative to host mRNA remains to be elucidated. Whatever mechanism accounts for differential translational suppression of reovirus and cellular mRNA, the fact that it is absent in Ras-transformed cells suggests that it may be an important event following growth factor receptor signaling.
Why is reovirus inherently sensitive to the status of Ras and PKR?
The natural portal of entry for reovirus may explain why a preference for replication in Ras-transformed cells has not been overcome through evolution. Reovirus naturally infects intestinal epithelial cells lining the digestive tract (Rubin et al., 1985) . These highly proliferative cells migrate along the villus and undergo continual lysis and exfoliation. Since Ras signaling pathways respond to positive growth conditions and instigate cell cycle progression, it is possible that untransformed intestinal epithelial cells have sufficient Ras activity and PKR suppression to permit reovirus infection. The ability of s3 to reduce PKR activation to some extent may be sufficient to avoid PKR activation in the context of intestinal epithelial cells (Beattie et al., 1995) . In comparison, normal cells do not undergo rapid cell division, have low Ras activity and therefore remain resistant to reovirus infection. The unique intestinal environment may provide additional unforeseen explanations for why activated Ras signaling pathways are advantageous for reovirus replication.
When used as a cancer therapeutic, reovirus is administered directly into the tumor or blood system, and therefore encounters barriers distinct from the natural infection. In the context of reovirus infection in cells outside the intestine, this natural distinction between cells with and without activated Ras signaling pathways can be exploited to permit killing of cancer but not normal cells.
From in vitro data to in vivo application in cancer therapy
Reovirus was first assessed in vivo as an oncolytic agent in 1998. Regression of tumors established from v-erbB-transformed NIH-3T3 cells was found in 65-80% of immune deficient mice with a single intratumoral injection of reovirus . More importantly, regression of tumors in immune competent mice was also significant following repeated injections of reovirus. Strikingly, reovirus was also shown to eliminate distal or metastatic tumors in immune competent mice (Hirasawa et al., 2003) . The efficacy of reovirus oncolysis was enhanced by chemotherapeutic agents. When mice were exposed to reovirus prior to tumor implantation, which better mimics the natural scenario in humans, combined reovirus and chemotherapy was able to overcome the immune-mediated clearing of reovirus. These studies underscore the potential application of reovirus for cancer therapy.
As mentioned previously, mutations in the Ras protooncogene and other components in the Ras signaling pathway are frequently associated with cancer. Thus, since the initial experiments performed on murine Rastransformed cells in the mouse animal model, several human cancer cell lines have been evaluated for their selective sensitivity to reovirus oncolysis. Several human colorectal cancer and ovarian carcinoma cell lines showed both increased Ras activity and sensitivity to reovirus oncolysis as compared with normal ovarian and colon cell lines in vitro . Tumor xenografts established from these cancer cell lines showed significant regression following both intraneoplastic and intravenous inoculation of reovirus. Successful oncolysis in additional studies using breast-tumor, glioblastoma and medulloblastoma (common pediatric brain tumor) derived cells extends the potential human targets for reovirus therapy against tumors and metastases Norman et al., 2002; Yang et al., 2003 Yang et al., , 2004 .
One potential obstacle to the use of viruses in clearing cancer is that such a treatment may select for cancer cells resistant to viral infection. Reovirus is predominantly associated with a productive, lytic infection. In cell culture, however, a few cells become persistently infected with reovirus (Ahmed et al., 1981; Kauffman et al., 1983; Dermody et al., 1993) . Although the prevalence of persistent infections in vivo is not known, it is important to assess the potential outcome of reovirus persistence during viral oncolysis. Unpublished data by Alain et al. show that the few Burkitt lymphoma (Raji) cells resistant to killing due to a persistent infection with reovirus were no longer tumorigenic in mice. This fascinating finding suggests that persistent infections, if they do occur in vivo, would not be detrimental to the use of reovirus as a cancer therapeutic. Furthermore, when persistently infected cells were cured of reovirus infection, they regained tumorigenic properties but were once again sensitive to reovirus oncolysis in vivo. This finding suggests that persistent reovirus infections do not pose a threat to the efficacy of reovirus cancer therapy, and suggests an interesting novel relationship between reovirus persistence and tumorigenicity.
Promising results with reovirus oncolysis in mouse models gave way to the testing of reovirus safety in both nonprimate hosts and a phase I human clinical trial . Results from the first phase I clinical trial on 18 terminal cancer patients showed that direct injection of reovirus into subcutaneous tumors has no toxic effects. Although reovirus replication and tumor regression looked promising in this study, these results are not statistically significant. Reovirus oncolysis is presently in phase I clinical trials for intravenous inoculation and phase II trials for recurrent malignant gliomas.
Conclusions
This review on reovirus oncolysis aims to demonstrate how the study of oncolytic viruses and cancer converge. Understanding determinants of transformation permits identification and/or engineering of oncolytic viruses. In turn, investigations on the mechanisms of selective viral oncolysis help unravel the complex cellular pathways involved in cellular transformation, identify new targets for cancer therapy and suggest which cancer backgrounds are compatible with viral oncolysis strategies.
The outcome of viral infection relies heavily on cellular processes. Therefore, viruses with an evolved or engineered preference for conditions established in cancer cells provide a powerful tool for selective cancer mining. Innumerable cellular changes are required for the establishment of tumorigenesis. The key to the development and use of viruses as oncolytic agents is, therefore, to understand the unique conditions in transformed cells that prove significantly advantageous to virus replication.
Extensive progress has been made regarding the mechanism(s) of selective viral oncolysis. The diversity of cellular and viral factors found to contribute to conditional virus replication in transformed cells is very intriguing. While the status of p53 pathways and nuclear export of viral mRNA have been associated with efficient replication of E1B-55K deleted adenovirus (ONYX-015), other recombinant adenoviruses containing deletions in E1A have been shown to preferentially replicate in tumor cells due to aberrances in the retinoblastoma protein (Heise et al., 2000; McCormick, 2000; O'Shea et al., 2004) . Selective replication of oncolytic measles virus has very recently been associated with increased CD46 receptor density on tumor cells (Anderson et al., 2004) . At the same time, activated Ras signaling cascades and/or dysregulated translational are involved in selective oncolysis by several viruses discussed in this review, suggesting an important role for these processes in virus replication and cellular transformation.
Why is dysregulated translation a common emerging theme in viral oncolysis? Protein synthesis control is a major cellular process that is altered during transformation. Changes in translation regulation are not only a consequence of transformation, but can cause tumorigenesis as well. Therefore, it is not surprising that antiviral mechanisms lead to blocked viral protein synthesis in normal cells, and that in transformed cells, dysregulated translation and compromised antiviral mechanisms converge to allow successful virus replication. Forthcoming research will delineate the specific mechanisms by which reovirus exploits malfunctioning cellular processes for efficient replication. Research on reovirus oncolysis may also reveal additional commonalities among oncolytic viruses.
